全文获取类型
收费全文 | 4456篇 |
免费 | 462篇 |
国内免费 | 101篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 165篇 |
妇产科学 | 25篇 |
基础医学 | 423篇 |
口腔科学 | 104篇 |
临床医学 | 286篇 |
内科学 | 265篇 |
皮肤病学 | 128篇 |
神经病学 | 114篇 |
特种医学 | 534篇 |
外国民族医学 | 6篇 |
外科学 | 393篇 |
综合类 | 515篇 |
现状与发展 | 1篇 |
预防医学 | 224篇 |
眼科学 | 63篇 |
药学 | 216篇 |
4篇 | |
中国医学 | 109篇 |
肿瘤学 | 1409篇 |
出版年
2024年 | 4篇 |
2023年 | 39篇 |
2022年 | 49篇 |
2021年 | 117篇 |
2020年 | 101篇 |
2019年 | 85篇 |
2018年 | 120篇 |
2017年 | 137篇 |
2016年 | 100篇 |
2015年 | 116篇 |
2014年 | 212篇 |
2013年 | 339篇 |
2012年 | 198篇 |
2011年 | 235篇 |
2010年 | 180篇 |
2009年 | 175篇 |
2008年 | 208篇 |
2007年 | 182篇 |
2006年 | 159篇 |
2005年 | 189篇 |
2004年 | 150篇 |
2003年 | 134篇 |
2002年 | 160篇 |
2001年 | 123篇 |
2000年 | 121篇 |
1999年 | 91篇 |
1998年 | 76篇 |
1997年 | 80篇 |
1996年 | 88篇 |
1995年 | 95篇 |
1994年 | 69篇 |
1993年 | 52篇 |
1992年 | 61篇 |
1991年 | 59篇 |
1990年 | 57篇 |
1989年 | 55篇 |
1988年 | 56篇 |
1987年 | 60篇 |
1986年 | 44篇 |
1985年 | 78篇 |
1984年 | 60篇 |
1983年 | 63篇 |
1982年 | 64篇 |
1981年 | 51篇 |
1980年 | 52篇 |
1979年 | 38篇 |
1978年 | 16篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 6篇 |
排序方式: 共有5019条查询结果,搜索用时 31 毫秒
1.
《Cancer radiothérapie》2022,26(4):542-546
PurposeModerate hypofractionated radiotherapy has become routine practice for a selected population of patients treated for early-stage breast cancer. In April 2020, the Fast Forward (FF) study was published which introduced another extreme hypofractionated radiotherapy regimen in five sessions over a week. The aim of this work is to evaluate the population of first patients in whom this regimen was used in our department, as well as the results in terms of early toxicity.Material and methodsWe retrospectively analysed all the patients treated in our department according to the Fast Forward protocol after establishing an institutional consensus regarding the selection of patients with breast cancer without indication for lymph node irradiation. All patients received breast-only irradiation at a total dose of 26 Gy in five fractions according to protocol. All patients were treated by modern conformational techniques with planning large volume coverage between 95 and 100%. Acute toxicity of the treatment was assessed using the NCI CTC v4.0 scale and the general condition was assessed according to the WHO classification.ResultsBetween August 2020 and May 2021, 30 patients were included, treated on the breast alone without complement on the tumour bed or irradiation of the lymph node areas. The median age of the patients was 80 years (range: 60–85 years) with performance status 2 in 27 cases (89%). Only one patient had metastatic disease (3%), one patient presented locally advanced and 28 (94%) patients had early stage disease. Three patients (10%) were treated in dorsal decubitus according to the “field in the field” technique and 27 patients (90%) in isocentric lateral decubitus, which made it possible to avoid the organs at risk such as the heart (average dose of less than 1 Gy) and the lungs. The early toxicity observed was grade I radio dermatitis in 8 patients (27%). No grade 2 and 3 toxicity, as well as radiation-induced pain or lymphedema were observed.ConclusionsThe results of this series of patients treated with hypofractionated radiotherapy according to the Fast Forward protocol on the breast alone with adapted techniques show that the protocol is feasible, with little early toxicity but a greater follow-up is necessary to assess long-term toxicity. 相似文献
2.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
3.
4.
Nicolas Zhou Matthew Bott Bernard J. Park Eric Vallières Candice L. Wilshire Kazuhiro Yasufuku Jonathan D. Spicer David R. Jones Boris Sepesi 《The Journal of thoracic and cardiovascular surgery》2021,161(3):760-771.e2
BackgroundAdjuvant chemotherapy, postoperative radiation (PORT), and prophylactic cranial irradiation (PCI) have been individually examined in limited-stage small cell lung cancer (SCLC). There is a paucity of data on the effectiveness of each adjuvant treatment modality when used in combination after surgical resection of SCLC.MethodsData were collected from 5 cancer centers on all patients with limited-stage SCLC who underwent surgical resection between 1986 and 2019. Univariate and multivariable models were conducted to identify predictors of long-term outcomes, focusing on freedom from recurrence and survival benefit of adjuvant chemotherapy, PORT, and PCI.ResultsA total of 164 patients were analyzed. Multivariable Cox regression analysis did not identify any adjuvant therapies to significantly influence recurrence in this cohort. Specifically, PORT was not associated with a significant influence on locoregional recurrence and PCI was not significantly associated with intracranial outcomes. Adjuvant chemotherapy improved survival in all stage I through III disease (hazard ratio, 0.49; 95% confidence interval, 0.29-0.81; P = .005) and even in pathologically node negative patients (hazard ratio, 0.49; 95% confidence interval, 0.27-0.91; P = .024). Although PCI was found to improve survival in univariate analysis, it was not significant in a multivariable model. PORT was not found to affect survival on either univariate or multivariable analysis.ConclusionsThis is among the largest multi-institutional studies on surgically resected limited-stage SCLC. Our results highlight survival benefit of adjuvant chemotherapy, but did not identify a statistically significant influence from mediastinal PORT or PCI in our cohort. Larger prospective studies are needed to determine the benefit of PORT or PCI in a surgically resected limited-stage SCLC population. 相似文献
5.
David C. Shoults Nicholas J. Ashbolt 《International journal of hygiene and environmental health》2019,222(1):111-116
UV disinfection is a relatively simple and cost-efficient disinfection method, especially for in-home greywater treatment. In this study, a bench scale experiment was performed using a LED collimated UV-C beam with a peak wavelength of 256?nm to determine if potentially pathogenic bacteria such as Staphylococcus aureus may become enriched in a semi-recirculating greywater system with UV as the sole disinfection step. A statistically significant (P?<?0.001) decreasing trend in UV-C efficacy was observed between the 1st and 6th UV exposure-growth cycles of S. aureus (ATCC 25923), resulting in a 1.5 decrease in log10 removal (P?<?0.00000) by the 5th iteration. An eleven-point dose-response curve of the 7th iteration of S. aureus was estimated and compared to the dose-response curve of the original strain; due to a longer apparent shoulder period and a decay constant of lesser degree, the dose required for a 4-log reduction of the enriched S. aureus was estimated to be ~1.9 times greater (22.0?mJ?cm?2 versus 11.8?mJ?cm?2). However, experimental results with S. epidermidis (ATCC 12228) and two wild strains, S. aureus and S. warneri, exhibited no trend of increased resistance. UV doses exceeding 20?mJ?cm?2 are generally sufficient in achieving a 4-log reduction of bacteria in drinking water systems; however, the results exhibited in this study suggest that when recirculation is involved, there may be a need for UV doses exceeding what is necessary for a 4-log reduction to suppress the enrichment of strains which could pose a public health risk. 相似文献
6.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(8):1599-1622
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non–small-cell lung cancer. SCLC has high metastatic potential, resulting in a clinically poor prognosis. Early concurrent chemo-radiation is the standard of care for limited-stage SCLC (LS-SCLC). Prophylactic cranial irradiation (PCI) is recommended for patients with LS-SCLC without progression of disease after initial therapy. A combination of etoposide and cisplatin or carboplatin remains the mainstay of first-line treatment for ES-SCLC, with the addition of atezolizumab, now becoming standard. Most SCLCs initially respond to therapy but almost invariably recur. Topotecan and amrubicin (in Japan) remain the primary chemotherapy options for relapsed SCLC. Immunotherapy, including nivolumab with or without ipilimumab, is now available for refractory disease. In general, the poor prognosis of SCLC has not improved significantly for more than 3 decades. Recently, next-generation molecular profiling studies have identified new therapeutic targets for SCLC. A variety of proapoptotic agents, compounds capitalizing on DNA-repair defects, immunotherapy agents, and antibody–drug conjugates are being evaluated in SCLC, with a number of them showing early promise. 相似文献
7.
8.
目的探讨接受选择性淋巴结照射(ENI)的食管鳞癌患者预后和失败模式。方法回顾性分析2005年1月至2012年12月河北医科大学第四医院收治的179例符合入组条件的食管鳞癌患者,分析肿瘤局部相关因素预测患者预后的价值,分析影响患者近期疗效、预后的影响因素,并对影响患者总生存率(OS)、无进展生存率(PFS)和复发的指标分别进行单因素和多因素分析。结果全组患者1、3、5年OS和PFS分别为77.1%、40.1%、26.0%和62.6%、30.6%、20.3%。多因素分析结果显示声音嘶哑、cN分期、cTNM分期、GTV-横径(GTV-D)和GTV-体积/长度(GTV-V/L)为影响患者OS的独立性影响因素(P<0.05);声音嘶哑、cTNM分期和近期疗效为影响患者PFS的独立性影响因素(P<0.05)。全组有75例(41.9%)患者出现复发,61例(34.1%)远处转移,其中19例(10.6%)为合并复发和远处转移。75例复发患者中64例(85.3%)患者为单纯食管复发,4例(5.3%)为单纯淋巴结复发,另7例(9.3%)患者为食管合并淋巴结复发。治疗后达完全缓解(CR)的63例患者中有18例患者出现复发,其中仅有2例患者出现淋巴结复发;logistic多因素分析结果显示患者周边组织/器官受侵、GTV-D和近期疗效为影响患者复发的独立性影响因素(P<0.05)。结论食管鳞癌患者接受ENI确实可行,其失败主要模式仍为食管复发;治疗前声音嘶哑、GTV-D和GTV-V/L较大、临床分期较晚和近期疗效不佳为患者预后较差的指标;肿瘤周边组织受侵、GTV-D和近期疗效是影响患者失败的独立性因素。 相似文献
9.
BackgroundProphylactic cranial irradiation (PCI) reduces brain metastasis incidence in lung cancer, however with risk of neurocognitive decline. Nevertheless, risk factors for neurocognitive decline after PCI remain unclear.MethodsWe systematically reviewed the PubMed database according to the PRISMA guideline. Inclusion criteria were: randomized clinical trials (RCTs) and observational/single arm trials evaluating PCI, including ≥20 patients, reporting neurocognitive test results for lung cancer. Primary aim: evaluate risk factors associated with neurocognitive decline after PCI.ResultsTwenty records were eligible (8 different RCTs, 8 observational studies), including 3553 patients in total (858 NSCLC, 2695 SCLC) of which 73.6% received PCI. Incidence of mild/moderate cognitive decline after PCI varied from 8 to 89% (grading not always provided); for those without PCI, this was 3.4–42%. Interestingly, 23–95% had baseline cognitive impairment. Risk factors were often not reported. In one trial, both age (>60 years) and higher PCI dose (36 Gy) including twice-daily PCI were associated with a higher risk of cognitive decline. In one trial, white matter abnormalities were more frequent in the concurrent or sandwiched PCI arm, but without significant neuropsychological differences. One trial identified hippocampal sparing PCI to limit the neurocognitive toxicities of PCI and another reported an association between hippocampal dose volume effects and memory decline. As neurocognition was a secondary endpoint in most RCTs, and was assessed by various instruments with often poor/moderate compliance, high-quality data is lacking.ConclusionsAge, PCI dose, regimen and timing might be associated with cognitive impairment after PCI in lung cancer patients, but high-quality data is lacking. Future PCI trials should collect and evaluate possible risk factors systematically. 相似文献
10.
目的探讨蓝光照射联合白蛋白治疗新生儿黄疸的临床效果。方法选取2018年1月—2018年12月医院收治的136例新生儿黄疸患儿,按随机数字表法分为A组(68例)和B组(68例),A组采取蓝光照射进行治疗,B组在此基础上联合白蛋白进行治疗,并比较不同组患儿治疗疗效。结果B组患儿治疗有效率较A组明显增加(P<0.05);B组患儿治疗前间接胆红素(IBIL)、总胆红素(TBIL)、γ-谷氨酰基转移酶(γ-GT)、游离脂肪酸(FFA)和超敏C反应蛋白(hsCRP)水平比较差异无统计学意义(P>0.05),治疗后B组患儿IBIL、TBIL、γ-GT、FFA和hs-CRP水平明显小于A组(P<0.05)。结论蓝光照射联合白蛋白静滴治疗新生儿黄疸临床疗效较好,有助于减轻胆红素水平以及改善临床症状。 相似文献